Hepatitis B surface antigen levels during natural history of chronic hepatitis B: A Chinese perspective study

World Journal of Gastroenterology

Volumn , Issue 27, 2014, Pages 9178-9184

  Zeng, Lin Yan ^a   Lian, Jiang Shan ^a   Chen, Jian Yang ^a   Jia, Hong Yu ^a   Zhang, Yi Min ^a   Xiang, Dai Rong ^a   Yu, Liang ^a   Hu, Jian Hua ^a   Lu, Ying Feng ^a   Zheng, Lin ^a   Li, Lan Juan ^a   Yang, Yi Da ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; Hepatitis B surface antigen quantification; Natural history; Perspective

Indexed keywords

HEPATITIS B (E) ANTIGEN; HEPATITIS B SURFACE ANTIGEN; UNCLASSIFIED DRUG; VIRUS DNA; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; HEPATITIS B(E) ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CHINA; CROSS-SECTIONAL STUDY; FEMALE; GENOTYPING TECHNIQUE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; VIRUS LOAD; ADOLESCENT; BLOOD; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CHINA; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TIME FACTORS; VIRAL LOAD; YOUNG ADULT;

EID: 84905389996     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i27.9178     Document Type: Article

References (26)

1. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51-68 [PMID: 10704474]
2. Nguyen DH, Ludgate L, Hu J. Hepatitis B virus-cell interactions and pathogenesis. J Cell Physiol 2008; 216: 289-294 [PMID: 18302164 DOI: 10.1002/jcp.21416]
3. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57 : 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]
4. Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver Int 2013; 33 Suppl 1: 125-132 [PMID: 23286856 DOI: 10.1111/liv.12075]
5. Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients. Clin Liver Dis 2013; 17: 399-412 [PMID: 23905812 DOI: 10.1016/j.cld.2013.05.006]
6. Chevaliez S . Is HBsAg quantification ready, for prime time? Clin Res Hepatol Gastroenterol 2013; 37: 559-563 [PMID: 23932705 DOI: 10.1016/j.clinre.2013.07.004]
7. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, Bonino F. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263-270 [PMID: 11830339]
8. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-1157 [PMID: 19115222 DOI: 10.1002/hep.22744]
9. Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Akarca US, Flisiak R, Verhey E, Van Vuuren AJ, Boucher CA, ter Borg MJ, Janssen HL. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454-461 [PMID: 20683945 DOI: 10.1002/hep.23722]
10. Xun YH, Zang GQ, Guo JC, Yu XL, Liu H, Xiang J, Liu J, Shi JP. Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers. J Gastroenterol Hepatol 2013; 28: 1746-1755 [PMID: 23800140 DOI: 10.1111/jgh.12304]
11. Kuo A, Gish R. Chronic hepatitis B infection. Clin Liver Dis 2012; 16: 347-369 [PMID: 22541703 DOI: 10.1016/j.cld.2012.03.003]
12. Liu J, Fan D. Hepatitis B in China. Lancet 2007; 369: 1582-1583 [PMID: 17499584 DOI: 10.1016/S0140-6736(07)60723-5]
13. Borgia G, Gentile I. Treating chronic hepatitis B: today and tomorrow. Curr Med Chem 2006; 13: 2839-2855 [PMID: 17073632]
14. Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline on prevention and treatment of chronic hepatitis B in China (2005). Chin Med J (Engl) 2007; 120: 2159-2173 [PMID: 18167196]
15. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283 [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3]
16. Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R, Flisiak R, Bock CT, Manns MP, Wedemeyer H, Cornberg M. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514-522 [PMID: 20207438 DOI: 10.1016/j.jhep.2010.01.014]
17. Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, Levy M, Locarnini SA. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52: 508-513 [PMID: 20206400 DOI: 10.1016/j.jhep.2010.01.007]
18. Ramachandran J, Ismail AM, Chawla G, Fletcher GJ, Goel A, Eapen CE, Abraham P. Serum HBsAg quantification in treatment-naïve Indian patients with chronic hepatitis B. Indian J Gastroenterol 2014; 33: 131-135 [PMID: 24052375 DOI: 10.1007/s12664-013-0395-1]
19. Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, Wong GL, Sung JJ. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-1468 [PMID: 18054753 DOI: 10.1016/j.cgh.2007.09.005]
20. Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W, Manns MP, Wedemeyer H, Naoumov NV. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52: 1611-1620 [PMID: 20931556 DOI: 10.1002/hep.23905]
21. Lee JM, Ahn SH, Kim HS, Park H, Chang HY, Kim do Y, Hwang SG, Rim KS, Chon CY, Han KH, Park JY. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011; 53 : 1486-1493 [PMID: 21520167 DOI: 10.1002/hep.24221]
22. Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, Slavin J, Bowden S, Gane EJ, Abbott W, Lau GK, Lewin SR, Visvanathan K, Desmond PV, Locarnini SA. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51: 1933-1944 [PMID: 20512987 DOI: 10.1002/hep.23571]
23. Lee JM, Ahn SH. Quantification of HBsAg: basic virology for clinical practice. World J Gastroenterol 2011; 17: 283-289 [PMID: 21253386 DOI: 10.3748/wjg.v17.i3.283]
24. Larsson SB, Eilard A, Malmström S, Hannoun C, Dhillon AP, Norkrans G, Lindh M. HBsAg quantification for identification of liver disease in chronic hepatitis B virus carriers. Liver Int 2013; Epub ahead of print [PMID: 24118747 DOI: 10.1111/liv.12345]
25. Papatheodoridis GV, Manesis EK, Manolakopoulos S, Elefsiniotis IS, Goulis J, Giannousis J, Bilalis A, Kafiri G, Tzourmakliotis D, Archimandritis AJ. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology 2008; 48 : 1451-1459 [PMID: 18924246 DOI: 10.1002/hep.22518]
26. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, Luo KX, Paik SW, Liaw YF, Button P, Popescu M. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47 : 428-434 [PMID: 18220290 DOI: 10.1002/hep.22065]